All News
Sjogren’s disease: two drugs with positive trials
After several failures of therapies in Phase 3 trials of Sjogren’s disease (SjD) over many years, all hope is not lost!
Read Article
Stopping therapy in GCA
They say the easiest bit about GCA, like PMR, is the first week after you start steroids. Those fond memories belie the challenge of ongoing treatment in GCA. In a steroid-only world, there is only misery. Steroid-sparing therapies have changed this completely.
Read Article
Is Low Disease Activity Low Enough?
Drs. Jonathan Kay and Joel Kremer discuss abstract 0449, "Consistency of CDAI Low-Disease Activity (LDA) Outcomes with Time in a Large US Registry: Association With Patient-Reported Clinical Outcomes and Measures of Quality of Life". #ACR25 https://t.co/kI8qOYjVL4
Dr. John Cush RheumNow ( View Tweet)
#ACR25 Sheds Light on Disparities, Age-Related Trends, and Epidemiology in Autoimmune Rheumatic Diseases At #ACR25, new research explored critical disparities and epidemiologic trends shaping outcomes in autoimmune rheumatic diseases across diverse populations and age groups. https://t.co/CPob0ppjv3
Dr. John Cush RheumNow ( View Tweet)
Hospitalization in Stills: Is it "Still" an infection?
Dr. Janet Pope discusses abstract 0163, "Trends in hospitalization and outcomes among patients admitted with Adult-onset Still’s disease in the United States: INSIGHTS FROM THE NATIONAL INPATIENT SAMPLE (2016-2022)," https://t.co/3Z0U9XN3nx
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid arthritis and the ‘big bang’ at #ACR25!
Is there ‘bang for the buck’ using big data to help predict who will develop RA in at-risk populations and similarly to predict response to csDMARDs, TNFi and JAKi in RA?
https://t.co/QDvdiP3q9R https://t.co/cz4j4vZkSd
Dr. John Cush RheumNow ( View Tweet)
GLP-1 Receptor Agonists in PsA: Mortality and MACE https://t.co/GtTGHY7j5g
@synovialjoints discussed TriNetX data base looking at GLP-1 medications effect on MACE in PsA patients.
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
From Fitbit to first diagnosis: AI is rewriting the RA playbook
Two studies presented at this year’s #ACR25 meeting highlight just how close we may be to a future where algorithms flag disease before we can and monitor activity with minimal patient burden. https://t.co/8AwBZkyZIW
Dr. John Cush RheumNow ( View Tweet)
New Insights into Pregnancy Outcomes and Maternal-Fetal Health in Rheumatic Diseases
At #ACR25, the ACR presented new research illuminating critical challenges and advances in pregnancy outcomes for women living with rheumatic diseases, including axial spondyloarthritis, https://t.co/nJjtTMHnD3
Dr. John Cush RheumNow ( View Tweet)
Abstract 1563: Ongoing Phase 1/2 trial of Rese-cel CAR-T in systemic sclerosis
🔹Pt with severe skin involvement showed improvement in mRSS (42→34), PFTs & nailfold capillaroscopy at 6 mo
🔹Grade 2 CRS, no ICANS or DLT reported
Early but exciting findings
@RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
#SLE #DORIS #remission is RARE and without #prednisone even rarer
#ASIA #Pacific 5K pts over 10 yrs
A call to do better
82% LLDAS, 70% remission, 31% GC-free remission (REM-0) at least once
abst#595 @ACRheum @RheumNow
#ACRBest https://t.co/OK6sYnqs81
Janet Pope Janetbirdope ( View Tweet)
Meta analysis evaluating age specific incidence across multiple registries (n=882)
Incidence 9.3 for women & 1.4 for men per 100k person-years
1. Wider distribution than I would have guessed
2. Much less age-dependency for men
@RheumNow #ACR25 Abstr#29W06 https://t.co/46dNGBZ45V
Links:
Mike Putman EBRheum ( View Tweet)
In AxSpA, an 8-week personalized exercise program improved trunk strength (+14.1%), mobility (+14.9%), and cardiorespiratory fitness ( increased oxygen pulse, ventilatory efficiency, anaerobic threshold). BASDAI and chest expansion also improved. Supports tailored rehab based on https://t.co/jawosa2AJK
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
#Ianalumab decreases disease activity in active #Sjögren's #disease
2 phase3 DB #RCT added to #SoC in primary #SjD
>90% #Ro+
+#ESSDAI in monthly sc dosing vs placebo,
Many 2ndary outcomes improved, safe
LB#24 #ACR25 @ACRheum @RheumNow
#ACRBest https://t.co/Z4ooUg7Nos
Links:
Janet Pope Janetbirdope ( View Tweet)
#Deucravacitinib #Tyk2i in active #PsA to 52weeks
#PBO was crossed over at 16weeks
Ongoing improvement for high bar outcomes ex % in #minimal #disease #activity #MDA
#Xray #progression was reduced with real data (not imputed)
#ACR2025 @RheumNow @ACRheum https://t.co/kAMym2x8HQ
Links:
Janet Pope Janetbirdope ( View Tweet)
McDermott et al. Target trial emulation of different b/tsDMARDs in RA-ILD. RTX as SOC. No significant differences seen in hospitalisation or death. Trends to abatacept and JAKi looking better... @RheumNow #ACR25 Abstr#2662 #ACRBest https://t.co/ghHEKztvgz
Richard Conway RichardPAConway ( View Tweet)
Biologic choice in PsA: consider factoring in obesity ⚖️
Abstract 2691: In a longitudinal cohort study, obesity associated with ↓ odds of achieving minimal disease activity (MDA) among pts on TNFi, but not with other DMARDs
@RheumNow #ACR25 https://t.co/p4KaH6HKYj
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
#2661 In >5000 veterans with RA-ILD, 8 distinct FVC trajectories were identified. >1/2showed a progressive decline (≥0.7%/yr). These progressive patterns predicted higher mortality & respiratory hospitalisations, underscoring major disease heterogeneity. @RheumNow #ACR25
Mrinalini Dey DrMiniDey ( View Tweet)
Abstract 2690: Food as a Medicine
Mediterranean vs low-calorie DASH vs control diet in PsA (multicenter RCT):
🔹 All 3 groups showed significant weight loss & DAPSA by wk 24
🔹 Weight loss not diet type may be the driver of clinical improvement
@RheumNow #ACR25 https://t.co/rBS3HR1HXl
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
Sooner May Still Be Too Late: Kidney Biopsies in SLE
#ACR25 kicked off with Plenary Session by Michelle Petri (Abstract 0772: Redefining When to Biopsy the Kidney in Patients with SLE. As part of a collaboration with the Accelerating Medicines Partnership, Petri and colleagues https://t.co/bU09vpcDew
Dr. John Cush RheumNow ( View Tweet)
